12 Dec 2019

Osteoporosis patients believe their condition is neglected and deprioritised by healthcare authorities

Read More
12 Dec 2019

European Commission Approves EVENITY[®] (Romosozumab) for the Treatment of Severe Osteoporosis in Postmenopausal Women at High Risk of Fracture

Read More
10 Dec 2019

UCB Presents Final Results from Phase II Study of Rozanolixizumab in Primary Immune Thrombocytopenia (ITP) at 2019 ASH Annual Meeting

Read More
6 Dec 2019

Bimekizumab Phase 3 Psoriasis Study Demonstrates Superiority Versus Humira[®]

Read More
15 Nov 2019

Bimekizumab Positive Results Confirmed in Second Phase 3 Psoriasis Study

Read More
8 Nov 2019

Transparency notifications BlackRock, Inc.

Read More
8 Nov 2019

UCB Presents New Data From Rheumatology Portfolio Addressing Unmet Needs in Axial Spondyloarthritis, Psoriatic Arthritis and Lupus at 2019 ACR/ARP

Read More
18 Oct 2019

Transparency notification Vanguard Health Care Fund

Read More
18 Oct 2019

EVENITY® (romosozumab) Receives Positive CHMP Opinion for the Treatment of Severe Osteoporosis in Postmenopausal Women at High Risk of Fracture

Read More
17 Oct 2019

Bimekizumab Phase 3 Psoriasis Study Meets All Endpoints, Achieving Significantly Greater Efficacy Versus Placebo and Ustekinumab

Read More
Subscribe to